Regenerative Therapy in Experimental Parkinsonism: Mixed Population of Differentiated Mouse Embryonic Stem Cells, Rather Than Magnetically Sorted and Enriched Dopaminergic Cells Provide Neuroprotection

CNS Neuroscience and Therapeutics

Volumn 20, Issue 8, 2014, Pages 717-727

  Tripathy, Debasmita ^a   Verma, Poonam ^a   Nthenge Ngumbau, Dominic N ^a   Banerjee, Meghna ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

6 OHDA induced hemiparkinsonism; Default differentiation; Embryonic stem cells; Intrastriatal transplantation; Manual magnetic cell sorting; Nigral neuronal loss; Retinoic acid

Indexed keywords

AMPHETAMINE; APOMORPHINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 2; OXIDOPAMINE; RETINOIC ACID; TRANSCRIPTION FACTOR NANOG; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT; NERVE PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CELL SELECTION; CONTROLLED STUDY; CORPUS STRIATUM; CULTURE MEDIUM; DOPAMINE BLOOD LEVEL; DOPAMINERGIC NERVE CELL; DRUG INFUSION; EMBRYONIC STEM CELL; ENGRAFTMENT; EXPERIMENTAL PARKINSONISM; GLIA CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGENERATIVE MEDICINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; STAINING; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; ANIMAL; BRAIN; CHEMICALLY INDUCED; CYTOLOGY; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; HEMISPHERIC DOMINANCE; INJURIES; MAGNETISM; MEDIAL FOREBRAIN BUNDLE; METABOLISM; NERVE CELL; PARKINSONIAN DISORDERS; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; APOMORPHINE; BRAIN; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOPAMINE; EMBRYONIC STEM CELLS; FUNCTIONAL LATERALITY; MAGNETICS; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE TISSUE PROTEINS; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION;

EID: 84904610289     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12295     Document Type: Article

References (38)

1. Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985;62:169-173.
2. Goetz CG, Olanow CW, Koller WC, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 1989;320:337-341.
3. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992;327:1541-1548.
4. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
5. Lindvall O. Developing dopaminergic cell therapy for Parkinson's disease - give up or move forward? Mov Disord 2013;28:268-273.
6. Tripathy D, Haobam R, Nair R, Mohanakumar KP. Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS ONE 2013;8:e72501.
7. Ko JY, Park CH, Koh HC, et al. Human embryonic stem cell-derived neural precursors as a continuous, stable, and on demand source for human dopamine neurons. J Neurochem 2007;103:1417-1429.
8. Park CH, Minn YK, Lee JY, et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 2005;92:1265-1276.
9. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004;101:12543-12548.
10. Doi D, Morizane A, Kikuchi T, et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012;30:935-945.
11. Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: Effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006;24:1433-1440.
12. + or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 2006;84:321-329.
13. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-493.
14. Borlongan CV, Sanberg PR. Elevated body swing test: A new behavioural parameter for rats with 6-OHDA induced parkinsonism. J Neurosci 1995;15:5372-5378.
15. Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocytes and micraglia, and reduces serotonin metabolism in 3-Nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 2014;20:10-19.
16. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998;12:905-912.
17. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. New York: Academic Press, 1982.
18. Hudson JL, van Horne CG, Stromberg I, et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993;626:167-174.
19. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl 1971;367:69-93.
20. Damjanov I, Fox N, Knowles BB, Solter D, Lange PH, Fraley EE. Immunohistochemical localization of murine stage-specific embryonic antigens in human testicular germ cell tumors. Am J Pathol 1982;108:225-230.
21. Solter D, Knowles BB. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci USA 1978;75:5565-5569.
22. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003;113:643-655.
23. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998;95:379-391.
24. Mendez JS, Finn BW. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. J Neurosurg 1975;42:166-173.
25. Blandini F, Cova L, Armentero MT, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010;19:203-217.
26. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev 2010;19:1017-1023.
27. Martínez-Cerdeño V, Noctor SC, Espinosa A, et al. Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesioned rats. Cell Stem Cell 2010;6:238-250.
28. Akerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001;21:8108-8118.
29. Nakao N, Yokote H, Nakai K, Itakura T. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor. J Neurosurg 2000;92:659-660.
30. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: Possible role of GDNF. J Neurochem 2003;85:299-305.
31. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005;11:703-704.
32. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005;102:216-222.
33. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell linederived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
34. Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005;23:862-871.
35. Rafuse VF, Soundararajan P, Leopold C, Robertson HA. Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog. Neuroscience 2005;131:899-916.
36. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestinpositive cells. FASEB J 2004;18:1237-1239.
37. Carlsson T, Carta M, Muñoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009;132:319-335.
38. Ganat YM, Calder EL, Kriks S, et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J Clin Invest 2012;122:2928-2939.